$VIE News
Last published 2mo ago
- 2mo agoVIEApproval of Uplizna, Bla #761142FDA Approved DrugsApproval Date: 09/03/2026; Drug Name: Uplizna, Bla #761142; Active Ingredients: INEBILIZUMAB-CDON; Company: Viela Bio; Submission Status: Approval; Application Number: 761142
- 5y agoVIEA Study of Single Ascending Doses of VIB1116 in Rheumatic Diseases - NCT04948099ClinicalTrials.govIncidence of treatment-emergent adverse events, serious adverse events, and adverse events of special interest, Serum concentration of VIB1116 and noncompartmental PK parameters, Change from baseline in the blood levels of plasmacytoid dendritic cells, (and 2 more...)
- 5y agoVIEA Phase 2 of VIB7734 for the Treatment of Moderate to Severely Active SLE - NCT04925934ClinicalTrials.govProportion of Participants who achieve BICLA and OGC (oral glucocorticoid) reduction response at Week 48, Proportion of Participants with CLASI-A score ≥ 10 at Baseline (Day 1) who achieve ≥ 50% reduction from Baseline (Day 1) in CLASI-A score at Week 12, Proportion of Participants achieving an SRI-4 response and an OGC dose ≤ 7.5 mg/day and ≤ Baseline (Day 1) dose of prednisone or equivalent at W ...
- 5y agoHZNPVIEHorizon Therapeutics plc Completes Acquisition of Viela Bio, Inc.Business WireDUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed the acquisition of Viela Bio, Inc. (Nasdaq: VIE) (“Viela”).
- 5y agoVIEViela Bio Reports Fourth Quarter and Full Year 2020 Operating and Financial ResultsGlobeNewswireGAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients...
- 5y agoVIEViela Bio Announces Additional Positive Results with UPLIZNA® (inebilizumab-cdon) in Patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 ForumGlobeNewswire-No new safety signals were identified with prolonged inebilizumab treatment and inebilizumab-mediated B-cell depletion- -UPLIZNA was shown to be safe and effective in patients with previous exposure...
- 5y agoVIEPTERVNCAmbrx Appoints Audit Executive Chris Nolet to Board of DirectorsBusiness WireSAN DIEGO--(BUSINESS WIRE)--Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s ...
- 5y agoVIEViela Bio to Report Fourth Quarter and Full Year 2020 Operating and Financial Results on March 1, 2021GlobeNewswireGAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients...
- 5y agoFSTGWPHHOLVIEMoore Kuehn Encourages FST, GWPH, HOL, and VIE Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
- 5y agoHZNPVIEHorizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine PortfolioBusiness WireDUBLIN & GAITHERSBURG, Md.--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) and Viela Bio, Inc. (Nasdaq: VIE) today announced the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and outstanding shares of Viela Bio, Inc. common stock for $53.00 per share in cash, which represents a fully diluted equity value of approximately $3.05 billi ...
- 6y agoVIEViela Bio Reports Third Quarter 2020 Financial Results and Program HighlightsGlobeNewswireGAITHERSBURG, Md., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune...
- 6y agoVIEViela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus ErythematosusGlobeNewswire-- VIB7734 potently depleted blood and tissue resident plasmacytoid dendritic cells, an important source of inflammatory mediators in autoimmune diseases -- -- Treatment with VIB7734 resulted in...
- 6y agoVIEViela Bio to Webcast Third Quarter 2020 Financial Results and Program Highlights on November 10, 2020GlobeNewswireGAITHERSBURG, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune...
- 6y agoVIEA Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease - NCT04540497ClinicalTrials.govTime to disease flare, defined as the time in days from Day 1 (dosing) to the date of the first treated and Adjudication Committee-determined IgG4 RD flare within the 52-week RCP.
- 6y agoVIEViela Bio Announces Data Presentations at the 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020GlobeNewswireGAITHERSBURG, Md., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune...
- 6y agoVIETreatment and Prevention of Acute Lung Injury (ALI) in Patients With SARS-CoV-2 Infection - NCT04526912ClinicalTrials.govNumber and proportion of participants who avoid endotracheal intubation and mechanical ventilation, Number and proportion of participants who avoid oxygen delivered by high-flow nasal cannula, Number and proportion of participants who avoid non-invasive positive pressure ventilation, (and 5 more...)
- 6y agoVIEMyasthenia Gravis Inebilizumab Trial - NCT04524273ClinicalTrials.govChange from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) Profile score., Change in Quantitative Myasthenia Gravis (QMG) scores., Proportion of subjects with both (1) ≥ 3-point improvement in MG-ADL and (2) no use of rescue therapy., (and 6 more...)
- 6y agoVIEViela Bio Reports Second Quarter 2020 Financial Results and Program HighlightsGlobeNewswireGAITHERSBURG, Md., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune...
- 6y agoVIEViela Bio to Webcast Second Quarter 2020 Financial Results and Program Highlights on August 12, 2020GlobeNewswireGAITHERSBURG, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune...
- 6y agoVIEViela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)GlobeNewswireGAITHERSBURG, Md., June 11, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNATM (inebilizumab-cdon) for the...
- 6y agoVIEApproval of UpliznablaFDA Approved DrugsApproval Date: 06/11/2020; Drug Name: Upliznabla; Company: Viela Bio; Submission Status: Approval; Application Number: 761142
- 6y agoVIEFDA Approves New Therapy for Rare Disease Affecting Optic Nerve, Spinal CordFDA Press ReleasesThe U.S. Food and Drug Administration today approved Uplizna (inebilizumab-cdon) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients with a particular antibody (patients who are anti-aquaporin-4 or AQP4 antibody positive). NMOSD is a rare autoimmune disease of the central nervous system that mainly affects the optic nerves and spinal ...
- 6y agoVIEViela Bio Announces Pricing of Public Offering of Common StockGlobeNewswireGAITHERSBURG, Md., May 27, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today...
- 6y agoVIEViela Bio Announces Proposed Public Offering of Common StockGlobeNewswireGAITHERSBURG, Md., May 26, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today...
- 6y agoVIEViela Bio Reports First Quarter 2020 Financial Results and Program HighlightsGlobeNewswireGAITHERSBURG, Md., May 13, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today...
- 6y agoVIEViela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus ErythematosusGlobeNewswire-Safety profile comparable to placebo control- -Potent depletion of plasmacytoid dendritic cells in peripheral blood and skin biopsies- -Dose-dependent improvements in Cutaneous Lupus Erythematosus...
- 6y agoVIEViela Bio, Inc. (VIE) CEO Bing Yao on Q4 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
- 6y agoVIEViela Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Business HighlightsGlobeNewswireGAITHERSBURG, Md., March 25, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today...
- 6y agoVIEViela Bio Reports Third Quarter 2019 Financial Results and Business HighlightsGlobeNewswireGAITHERSBURG, Md., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today...
- 7y agoVIEViela Bio Enters Strategic Collaboration with Mitsubishi Tanabe Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases in Japan and Other Asia RegionsGlobeNewswireViela Bio is eligible to receive an upfront licensing fee of $30 million as well as development and commercialization milestones and payments based, in part, on sales revenue GAITHERSBURG, M.D., Oct....
- 7y agoVIEViela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswireGAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq: VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases,...
- 7y agoVIEViela Bio Announces Pricing of Initial Public OfferingGlobeNewswireGAITHERSBURG, Md., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Viela Bio, Inc., a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced...